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Abstract
Factor (f)Xa is a critical enzyme in blood coagulation that is responsible for the initiation and propagation of thrombin
generation. Previously we have shown that analysis of computationally generated thrombin profiles is a tool to investigate
hemostasis in various populations. In this study, we evaluate the potential of computationally derived time courses of fXa
generation as another approach for investigating thrombotic risk. Utilizing the case (n=473) and control (n=426)
population from the Leiden Thrombophilia Study and each individual’s plasma protein factor composition for fII, fV, fVII,
fVIII, fIX, fX, antithrombin and tissue factor pathway inhibitor, tissue factor-initiated total active fXa generation was assessed
using a mathematical model. FXa generation was evaluated by the area under the curve (AUC), the maximum rate (MaxR)
and level (MaxL) and the time to reach these, TMaxR and TMaxL, respectively. FXa generation was analyzed in the entire
populations and in defined subgroups (by sex, age, body mass index, oral contraceptive use). The maximum rates and levels
of fXa generation occur over a 10- to 12- fold range in both cases and controls. This variation is larger than that observed
with thrombin (3–6 fold) in the same population. The greatest risk association was obtained using either MaxR or MaxL of
fXa generation; with an ,2.2 fold increased risk for individuals exceeding the 90
th percentile. This risk was similar to that of
thrombin generation(MaxR OR 2.6). Grouping defined by oral contraceptive (OC) use in the control population showed the
biggest differences in fXa generation; a .60% increase in the MaxR upon OC use. FXa generation can distinguish between a
subset of individuals characterized by overlapping thrombin generation profiles. Analysis of fXa generation is a phenotypic
characteristic which may prove to be a more sensitive discriminator than thrombin generation among all individuals.
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Introduction
The inventory of blood and vessel wall components associated
with the blood coagulation system for hemorrhage control is
extensive, and this inventory increases substantially with the
inclusion of intermediate species that emerge in the individual
processes leading to thrombin generation. Monitoring thrombin
generation has been the focus of providing a global description of
the blood coagulation process, due to the multifactorial nature of
thrombin in procoagulant, anticoagulant, fibrinolytic and cellular
events [1]. Thrombin’s critical role in maintaining hemostasis is
also exemplified by the use of antithrombotics to suppress
coagulation. Most of these agents target thrombin, platelets and,
more recently, factor (f)Xa [2].
Factor Xa can be thought of as the transducer of the thrombin
generation signal. The main function of fXa is to participate in the
prothrombinase complex (fXa-fVa-membrane-Ca
2+). Factor Xa is
the serine protease enzyme in the prothrombinase complex that
catalytically activates prothrombin to thrombin. Factor Xa is a
unique regulatory enzyme in that it is formed through both the
extrinsic tenase (tissue factor (Tf)-fVIIa-membrane-Ca
2+) and
intrinsic tenase (fVIIIa-fIXa-membrane-Ca
2+) complexes. During
the initial stages of the hemostatic event triggered by the exposure
of blood to Tf, low levels of both fXa and fIXa are generated [3].
Once generated, the limited amounts of fXa produced by the
extrinsic tenase bind to available membrane sites and convert
picomolar amounts of prothrombin to thrombin [4]. This
thrombin then activates fVIII and fV allowing the initial formation
of the intrinsic tenase and prothrombinase complexes. The burst
or propagation phase of thrombin generation depends upon the
additional fXa generated via the intrinsic tenase complex. The
intrinsic tenase complex activates fX at a 50- to 100- fold higher
rate than the extrinsic tenase complex [5–7]. This increased rate of
fXa generation overcomes the suppressive action of fXa inhibitors
such as tissue factor pathway inhibitor (TFPI) and antithrombin
(AT) resulting in increasing levels of prothrombinase and the
propagation of the procoagulant event. It has also been shown,
that the prothrombinase concentration is limited by the active fXa
concentration [8,9]. Thus, the termination of prothrombinase
activity is primarily a consequence of the inhibition of fXa.
Because fXa is a major player in the coagulation process, it has
been a target for regulation by synthetic inhibitors in treating
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are currently underway to clinically evaluate antithrombotic
agents that target fXa [10].
Prothrombin circulates in plasma at a concentration of 1.4 mM
(100 mg/mL) while the plasma concentration of circulating fX is
approximately 10-fold less (,170 nM, 10 mg/mL). Studies from a
number of experimental systems have indicated that as a
coagulation reaction proceeds, consumption of fX is quite limited
(,10%) in contrast to prothrombin [11]. The practical conse-
quence of this has been that measuring fX consumption or fXa
levels in coagulation reactions is technically more challenging than
monitoring prothrombin or thrombin products. There are
currently no widely accessible methods comparable to those that
directly monitor thrombin formation, such as thrombograms, or
that indirectly measure thrombin, such as thrombin-antithrombin
(TAT) complex measurements.
Factor X levels in healthy populations vary on average over a
two- to three-fold range. High levels of fX alone have been shown
to predict the risk of venous thrombosis, but were not a risk factor
for venous thrombosis when the levels of other vitamin K-
dependent proteins were taken into account [12]. Little is known
regarding the levels of fXa that are generated in healthy
individuals upon a tissue factor (Tf) stimulus, and how variations
in fXa may effect thrombin generation and the overall
procoagulant response leading to DVT. Methods that enable the
evaluation of fXa generation in individuals might add to our
understanding of variations in thrombin generation among
individuals and might help guide the use of fXa anticoagulants.
Mathematical modeling allows for these measurements and
comparisons. An empirically validated numerical model of the
extrinsic coagulation system [13–17] provides a method for
investigating fXa generation for profiles and patterns in a large
group of individuals. In this study, we used a mathematical model
that describes the Tf pathway of blood coagulation to evaluate fXa
generation in the Leiden Thrombophilia Study (LETS) cohort and
compare the results to previously analyzed thrombin generation in
this population [15]. This is the first study that we are aware of
that compares fXa generation to thrombin generation in the same
population using computational modeling approaches.
Materials and Methods
Study population
Our population was selected from the LETS case-control study
[18]. The healthy controls (n=474) were sex and age matched
acquaintances or partners of patients within the case group
(n=474, patients with an objectively diagnosed first deep vein
thrombosis). All individuals were younger than 72 years and did
not have active malignancy. Individuals on oral anticoagulation
(n=49) were excluded from these analyses, leaving 473 controls
and 426 patients.
Several individual characteristics were used to define subpop-
ulations. We separated the data by sex, age and body mass index.
When we investigated the effect of oral contraceptives we excluded
individuals who were pregnant, post-menopausal, within 30 days
postpartum or had a recent miscarriage at the time of thrombosis
for patients (index date). Since the median time between
occurrence of DVT and venipuncture was 18 months, we only
evaluated women who either used oral contraceptives at the index
date and the venipuncture date or did not at both dates. Seven
individuals were excluded from analyses involving alcohol since
information was missing, and three individuals were excluded
from analyses involving BMI who were not 18 at the time of the
blood draw. Factor Xa generation curves of each subpopulation
were generated by averaging fXa concentrations at each time
point. Subpopulation fXa profiles are shown in the figures as the
mean time point values with the 95% confidence interval.
Plasma composition
Citrated plasma previously collected from all individuals [18] was
used to determine the concentrations of the coagulation proteins fII,
fV, fVII, fVIII, fIX, fX, TFPI and AT as described in detail in
earlier studies performed using the LETS population (described in
[15]). In brief, fII activity was measured by a chromogenic assay.
Factor V, fIX, fX and TFPI were determined by antigen based
assays. Factor VII and fVIII levels were measured by one-stage
coagulation assays. Antithrombin was measured by a colorometric
assay (Coamate, Chromogenix, Mo ¨lnda, Sweden) [19]. All
procoagulant and anticoagulant protein levels were determined
for each individual and are shown as the mean (SD) and range in
Table 1.
Numerical simulations
The mathematical model is based upon prior publications by
Hockin et al. [13] and Butenas et al. [14] and yields concentration
versus time profiles for selected species when electronic mixtures of
procoagulant (fII, fV, fVII/fVIIa, fVIII, fIX and fX) and
anticoagulants (TFPI and AT) are exposed to a 5 pM Tf stimulus
(Figure 1). Factor levels expressed as a percentage were translated
into molar concentrations by using literature values for the mean
plasma concentrations [20]. Each individual’s plasma factor
composition was entered into the computer database, and
simulated reactions were initiated with Tf. Simulated reactions
were solved for total active fXa generation (free fXa and fXa in the
prothrombinase complex produced by both the extrinsic and
intrinsic tenase complexes) over a 3600 second time frame. The
outputs of these fXa profiles were evaluated by the maximum level
(MaxL-Xa) and rate (MaxR-Xa) of fXa generated, the time to
reach these values (TMaxL-Xa and TmaxR-Xa) and total fXa
(summing fXa concentrations at each time point: AUC).
A systematic analyses of the contribution of the plasma factors
to either the fXa or thrombin generation output was conducted on
the subgroups, as previously described [21,22], by adjusting the
factors to mean physiologic concentrations or to the relevant
control population and reevaluating the output.
Table 1. Plasma composition within either healthy controls
or individuals with a known DVT.
Controls: No Known DVT Prior DVT
Protein
Percentage
Mean (SD) Range
Percentage
Mean (SD) Range
FII 104 (15) 63–153 108 (17) 67–178
FV 131 (33) 47–302 133 (35) 41–305
FVII 110 (22) 41–171 114 (25) 53–200
FVIII 122 (33) 49–232 141 (35) 53–318
FIX 103 (21) 52–188 109 (26) 63–209
FX 103 (17) 49–163 107 (20) 58–174
AT 99 (10) 63–125 99 (11) 67–143
TFPI total 92 (21) 46–171 94 (21) 35–159
doi:10.1371/journal.pone.0029178.t001
Factor Xa Generation Versus Thrombin Generation
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Data are presented as mean (SD). The Kolmogorov-Smirnov
test was used to assess conformity with a normal distribution. The
t-test was utilized for comparisons between two groups provided a
normal distribution. Non-parametric methods were utilized if the
assumption of non-normality was not met. Significance was
defined as p,0.05. 90
th percentiles for MaxL, MaxR and AUC
were determined for the entire population. Odds ratios (signifying
the odds of being a case for those above the 90
th percentile vs those
with lower levels) were calculated for each parameter.
Results
Factor Xa generation
The fX activation profiles for all cases and controls are
represented separately in Figure 2 as a mean (SD) profile. The
extracted parameters for MaxR, TMaxR, MaxL, TMaxL and
AUC are presented in Tables 2 and 3. The MaxR-Xa generation
varied within the healthy control population by 12-fold (2.3–
28 pM/s; IQR: 5.6–9.5 pM/s; P10: 4.3 pM/s; P90: 12.4 pM/s)
and the MaxL-Xa varied over 10-fold (1.7–17 nM; IQR: 4.0–
6.9 nM; P10: 3.1 nM; P90: 9.0 nM). Within the same control
population using the same mathematical model, the range of
thrombin (IIa) generation was tighter for both the MaxR-IIa (1.1–
5.4 nM/s; IQR: 2.0–2.9 nM/s; P10: 1.7 nM/s; P90: 3.6 nM/s)
and the MaxL-IIa (158–669 nM; IQR: 313–414 nM; P10:
275 nM; P90: 462).
Within the case population (individuals with a known DVT),
MaxR-Xa generation also varied by 12-fold (of 2.1–25.1 pM/s)
and MaxL-Xa and AUC varied over 11-fold (1.7–18.6 nM and
4.5–51.8 mM*s, respectively). In comparison to thrombin gener-
ation in the case population, fXa discrimination was consistently
broader than thrombin generation; which showed only a 5.8 fold
variation in MaxR-IIa (11.3–65.3 nM/s) and 5.3 fold in MaxL-IIa
(170–903 nM) [21]. When evaluated by the odds ratio at a 90
th
percentile cut off, the OR for MaxR-fXa generation is 2.1 (95%
CI: 1.3–3.2) and for MaxL-fXa generation is 2.2 (95% CI: 1.4–3.4)
(Table 4). Thrombin generation MaxR had an OR of 2.6 (95%
Figure 1. Schematic of the computational model of the tissue factor pathway. The multicomponent processes encompassed in the
computational model are illustrated as either: enzymes (open circle), inhibitors (hatched circle), zymogens (open boxes) or complexes (open ovals).
Upon injury to the vessel wall, tissue factor, the cofactor for the extrinsic tenase complex, is exposed to circulating factor VIIa and forms the vitamin K
dependent complex the extrinsic tenase. Factor IX and factor X are converted to their serine proteases factor IXa (FIXa) and factor Xa (FXa) which then
form the intrinsic tenase and the prothrombinase complexes, respectively. The combined actions of the intrinsic and extrinsic tenase and the
prothrombinase complexes lead to an explosive burst of the enzyme thrombin (IIa). The procoagulant response is down regulated by the
stoichiometric inhibitors tissue factor pathway inhibitor (TFPI) and antithrombin (AT). TFPI serves to attenuate the activity of the extrinsic tenase
trigger of coagulation. AT directly inhibits thrombin, FIXa and factor Xa. The proteins in which the concentrations from individual subjects are used
are shown in red. Tissue factor in blue is arbitrarily set to 5 pM. Circulating FVIIa is set at 1% of the concentration of FVII from each individual.
doi:10.1371/journal.pone.0029178.g001
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parameters MaxR (95% CI for difference: 0.93–1.86 pM/s), MaxL
(95% CI for difference: 0.77–1.44 nM) and AUC (95% CI for
difference:2.075–3.925 mM*s)weresignificantlygreater inthecases.
Factor Xa generation segregated by clinical risk
categories
Factor Xa generation in individuals was analyzed by grouping
fXa generation profiles of individuals with shared clinical
characteristics (e.g. BMI, sex, age, oral contraceptive use) and
generating an average profile for the entire group analogous to our
previously published work for thrombin [15,21]. The results are
summarized in Tables 2 and 3 and described below.
Body mass index
Figure 3 panel A presents the computational analyses of fXa
generation when the control population is segregated into
individuals with either a BMI #26 kg/m
2 or a BMI .26 kg/m
2.
Figure 2. Factor Xa profiles of case and control individuals. Plasma compositions from 473 healthy individuals and 426 individuals with a
known DVT were used to generate time courses of total active fXa upon a Tf stimulus of 5 pM. The mean total active fXa level at each second is
shown with the standard deviation in grey.
doi:10.1371/journal.pone.0029178.g002
Table 2. Factor Xa generation outputs for healthy controls (no known DVT).
N
MaxR,
pM/s
mean (SD)
TMaxR,
s
mean (SD)
MaxL,
nM
mean (SD)
TMaxL,
s
mean (SD)
AUC
mM*s
mean (SD)
Whole population 473 8.0 (3.5) 636 (31) 5.8 (2.5) 1737 (203) 15.5 (6.7)
Sex
Men 201 7.2 (2.8)
{ 647 (29)
{ 5.3 (2.1)
{ 1769 (178)
{ 14.2 (5.7)
{
Women 272 8.5 (3.9) 629 (30) 6.2 (2.7) 1714 (216) 16.3 (7.2)
Females without OC 90 7.2 (2.3)
{ 633 (27)
{ 5.2 (1.7)
{ 1677 (153) 13.7 (4.7)
{
Females with OC 47 12.0 (5.4) 601 (27) 8.4 (3.5) 1630 (198) 22.2 (9.4)
Age (yrs)
#45 223 7.9 (3.9) 633 (33)
{ 5.7 (2.7) 1678 (158)
{ 15.0 (7.2)
.45 250 8.0 (3.1) 639 (28) 5.9 (2.2) 1790 (223) 15.9 (6.1)
BMI kg/m
2
#26 264 7.5 (3.4)
{ 638 (32) 5.4 (2.2)
{ 1699 (173)
{ 14.2 (6.0)
{
.26 193 8.6 (3.6) 633 (29) 6.4 (2.6) 1789 (227) 17.2 (7.1)
N: population size; BMI: Body Mass Index, OC: oral contraceptives, MaxR: maximum rate, TMaxR: time to maximum rate, MaxL: maximum level, TMaxL: time to maximum
level, AUC: area under the curve.
{p#0.001 when compared within each stratification,
{p,0.05.
doi:10.1371/journal.pone.0029178.t002
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thrombin generation analysis [15,21]. In the control group, for
every 1 unit increase in BMI, there was an average of a 0.138 pM/s
increase in MaxR (95% CI: 0.0577–0.2181), a 13 sec increase in
TML (95% CI: 8.516–17.528), a 0.372 mM*s increase in AUC
(95% CI: 0.223–0.522) and 0.128 nM increase in MaxL (95% CI:
0.0726–0.1832).
When cases and controls are compared (Table 4), individuals
with a lower BMI (#26 kg/m
2) showed an odds ratio of 2.4 (95%
CI: 1.1–4.9) for MaxR and 2.5 (95% CI: 1.1–5.6) for MaxL.
Thrombin generation, as previously reported, also showed a
greater risk prediction (MaxR OR: 2.9 (95% CI: 1.6–5.0)) in
individuals with a lower BMI #26 kg/m
2 [21]. However, unlike
thrombin, fXa generation for individuals whose BMI .26, both
MaxR and MaxL had 95% CIs encompassing 1.
Age
Figure 3 panel B presents the computational analyses of fXa
generation when the control population is segregated into age
categories of individuals .45 years old or 45 years old and
younger. In the control population, for every 1 year increase in
age, there was an average of a 0.381 sec increase in TMR (95%
CI: 0.172–0.591), and a 5.02 sec increase in TML (95% CI: 3.70–
6.34). MaxR, MaxL and AUC were not different. Both age groups
showed an elevated odds ratio for cases for both MaxR and MaxL
(Table 4). This was also true when thrombin generation as a risk
predictor was evaluated [21].
Sex and oral contraceptive use
When control women (n=272) are compared to men (n=201)
(Figure 3C), women generate fXa at a faster rate (8.5 (3.9) pM/s
versus 7.2 (2.8) pM/s; 95% CI for difference: 0.7–1.9 pM/s) and
reach higher levels (6.2 (2.7) nM versus 5.4 (2.1) nM; 95% CI for
difference: 0.4–1.2 nM). (Table 2).
When control premenopausal women aged 15 to 49 are split
into users and non-users of oral contraceptives (Table 2), we
observe the largest disparity in fXa generation among the clinical
risk categories that we evaluated (Figure 4A). When women on oral
contraceptives (n=47) were compared to women not on oral
contraceptives (n=90), fXa was generated at a faster MaxR (12.0
(5.4) pM/s versus 7.2 (2.3) pM/s; 95% CI for difference: 3.1–
6.4 pM/s) and a higher MaxL (8.4 (3.5) nM versus 5.2 (1.7) nM;
95% CI for difference: 2.2–4.3 nM) in women who took oral
contraceptives. The time to reach the maximum rate was
significantly faster in users (601 (27) s versus 633 (27) s; 95% CI
for difference: 23–42 s). In addition, more total fXa was generated
overthecourseoftheexperiment(22.2(9.4)vs.13.7(4.7) mM*s;95%
CI for difference: 5.6–11.4 mM*s). Thrombin generation was also
markedly enhanced in women who used oral contraceptives [21].
For this select group of premenopausal women not on oral
contraceptives, when women with a known DVT are compared to
control women, the OR for MaxL of fXa generation is 15.7 and
for MaxR is undefined since no controls (out of 90 individuals)
were above the 90
th percentile compared to cases (6 out of 40 were
above the cut off, Table 4). Thrombin generation measurements
for MaxR were similar in that no control individuals were present
at a 90
th percentile cut-off point [21].
Comparing factor Xa generation in control individuals
with equivalent thrombin generation profiles
To determine if fXa generation provides any additional
discrimination between individuals relative to thrombin genera-
tion, we reevaluated our previously determined thrombin
generation profiles [15] within the same control population. We
selected three pairs of thrombin generation profiles in which each
of the individual profiles within a pair were overlapping (Figure 5).
The first pair of individuals had overlapping thrombin profiles that
were generated more slowly (,120 s slower) than the mean time
to maximum level (dashed line, 432 s) of the healthy population.
The second pair of individuals yielded overlapping thrombin
generation curves comparable to the mean profile (dashed line).
The third pair of individuals yielded overlapping thrombin
generation curves that were faster (,60 s faster) than the mean
profile.
Table 3. Factor Xa generation outputs for individuals with a known DVT.
N
MaxR,
pM/s
mean (SD)
TMaxR,
s
mean (SD)
MaxL,
nM
mean (SD)
TMaxL,
s
mean (SD)
AUC
mM*s
mean (SD)
Whole population 426 9.4 (3.6) 634 (28) 6.9 (2.7) 1776 (243) 18.5 (7.4)
Sex
Men 172 8.6 (3.2)
{ 643 (26)
{ 6.4 (2.3)
{ 1828 (265)
{ 17.1 (6.3)
{
Women 254 9.9 (3.8) 627 (27) 7.3 (2.9) 1741 (221) 19.4 (7.9)
Females without OC 40 10.1 (3.8)
{ 626 (21)
{ 7.7 (3.0)
{ 1797 (206) 20.5 (8.3)
Females with OC 30 12.6 (5.1) 605 (21) 9.3 (4.0) 1711 (260) 25.0 (11.3)
Age (yrs)
#45 209 9.3 (3.7) 627 (27)
{ 6.8 (2.8) 1739 (269)
{ 18.1 (7.7)
.45 217 9.4 (3.5) 640 (27) 7.0 (2.6) 1812 (210) 18.8 (7.1)
BMI kg/m
2
#26 199 8.8 (3.4)
{ 634 (30) 6.4 (2.5)
{ 1734 (229)
{ 17.1 (6.7)
{
.26 216 9.9 (3.7) 633 (26) 7.4 (2.8) 1819 (252) 19.9 (7.7)
N: population size; BMI: Body Mass Index, OC: oral contraceptives, MaxR: maximum rate, TMaxR: time to maximum rate, MaxL: maximum level, TMaxL: time to maximum
level, AUC: area under the curve.
{p#0.001 when compared within each stratification,
{p,0.05.
doi:10.1371/journal.pone.0029178.t003
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overlapping pairs of thrombin generation curves, fXa generation
appears to discriminate between the individuals in two of the
groupings. There also appears to be a relationship between the
timing of thrombin generation and the level of fXa discrimination.
The greatest discrimination appears when the overlapping
thrombin generation profiles are faster than the mean of the
population (bottom row). These results show that fXa generation
can provide additional discrimination to thrombin generation
profiles. In addition, these studies were performed with a Tf-
initiator concentration of 5 pM to reflect empirically validated
data [13]. Additional discrimination is possible when Tf is
evaluated at varying Tf concentrations; further studies are
warranted to elucidate this effect.
We have previously demonstrated that the thrombin generation
profile is not dependent upon one factor alone, but the synergy
between all the factors [15]. We have shown that small differences
in the ensemble of factor levels, all within the normal range, can
lead to large differences in thrombin generation profiles
[15,16,21,22]. In this case, the focus is on the opposite effect.
That is, that when considerably different normal range ensembles
are evaluated with respect to thrombin generation potential, no
difference in thrombin generation is predicted. For example, the
plasma composition between the two individuals with the faster
Table 4. Comparison of fXa generation in individuals with a known DVT versus controls.
N
MaxR
Prevalence, %
MaxL
Prevalence, %
Whole population Controls 473 33 (7.5%) 32 (7.3%)
Cases 426 57 (15.4%) 58 (15.8%)
Fisher’s Exact p-value 0.0017 0.0008
OR (95% CI) 2.1 (1.3–3.2) 2.2 (1.4–3.4)
Sex/Men Controls 201 7 (3.5%) 7 (3.5%)
Cases 172 15 (8.7%) 14 (8.1%)
Fisher’s Exact p-value 0.046 0.070
OR (95% CI) 2.6 (1.1–6.7) 2.5 (0.97–6.2)
Sex/Women Controls 272 26 (9.6%) 25 (9.2%)
Cases 254 42 (16.5%) 43 (16.9%)
Fisher’s Exact p-value 0.019 0.009
OR (95% CI) 1.9 (1.1–3.2) 2.0 (1.2–3.4)
Females without OC Controls 90 0 (0%) 1 (1.1%)
Cases 40 6 (15%) 6 (15%)
Fisher’s Exact p-value 0.0006 0.0034
OR (95% CI) undefined 15.7 (1.8–135)
Females with OC Controls 47 14 (29.8%) 13 (27.6%)
Cases 30 11 (36.7%) 12 (40.0%)
Fisher’s Exact p-value 0.62 0.32
OR (95% CI) 1.4 (0.52–3.6) 1.7 (0.66–4.6)
Age#45 yrs Controls 223 17 (7.6%) 17 (7.6%)
Cases 209 31 (14.8%) 32 (15.3%)
Fisher’s Exact p-value 0.021 0.015
OR (95% CI) 2.1 (1.1–3.9) 2.2 (1.2–4.1)
Age.45 yrs Controls 250 16 (6.4%) 15 (6.0%)
Cases 217 26 (12.0%) 26 (12.0%)
Fisher’s Exact p-value 0.051 0.032
OR (95% CI) 2.0 (1.0–3.8) 2.1 (1.1–5.6)
BMI#26 kg/m
2 Controls 264 12 (4.5%) 10 (3.8%)
Cases 199 20 (10.1%) 18 (9.0%)
Fisher’s Exact p-value 0.026 0.029
OR (95% CI) 2.4 (1.1–4.9) 2.5 (1.1–5.6)
BMI.26 kg/m
2 Controls 193 20 (10.4%) 21 (10.9%)
Cases 216 35 (16.2%) 38 (17.6%)
Fisher’s Exact p-value 0.11 0.066
OR (95% CI) 1.7 (0.93–3.0) 1.8 (0.99–3.1)
OR: odds ratio calculated at the 90% cut off point; BMI: body mass index; OC: oral contraceptives.
doi:10.1371/journal.pone.0029178.t004
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follows: individual 1: fII 97%, fV 89%, fVII 157%, fVIII 137%,
fIX 87%, fX 134%, AT 99%, TFPI 64%; individual 2: fII 97%, fV
164%, fVII 131%, fVIII 188%, fIX 100%, fX 124%, AT 101%,
TFPI 87%. Striking differences in factor levels include fV (80%
difference), fVIII (35% difference) and TFPI (35% difference).
Although these thrombin profiles are virtually identical, when the
dynamics are evaluated using a different parameter (fXa) the two
individuals can be distinguished.
Identifying the compositional differences that drive the
alterations in fXa generation profiles
We have reported differences in thrombin generation profiles
between acute (ACS) and stable coronary artery disease (CAD)
populations [22] and have determined that in the ACS population,
the procoagulant phenotype seen with thrombin generation
profiles appears to depend primarily on the influence of AT,
fVIII and prothrombin. A similar analysis was performed here to
identify which protein(s) account for differences in fXa profiles
between oral contraceptive users and non-users (see Figure 4A).
The mean plasma composition of the oral contraceptive
population in controls was as follows: oral contraceptive users:
fII 106%, fV 112%, fVII 118%, fVIII 124%, fIX 115%, fX 118%,
AT 95%, TFPI 68%; non-users: fII 102%, fV 123%, fVII 104%,
fVIII 117%, fIX 92%, fX 96%, AT 100%, TFPI 86%. As
reported previously [15], when the factor levels are compared
between the groups differences are seen in fIX, fX, AT and TFPI.
When we evaluated the influence of the ensemble of plasma
composition on the fXa generation output, we determined that
that the increased fXa generation in women on oral contraceptives
was primarily driven by differences in the levels of fIX and TFPI
(Figure 6A). When the plasma composition accounting for the
thrombin generation profiles of oral contraceptive users was
similarly evaluated, the collective alteration of four factors (fIX,
TFPI, AT and II) to the non-users values was required to fully
normalize the thrombin generation output to that of the non-users
(Figure 6B). Thus the minimal set of factors required to normalize
fXa generation between the two populations is not equivalent to
the minimal set required to normalize thrombin generation.
Discussion
In this study we showed that there is a large variation in
predicted fXa generation in an apparently healthy population and
in individuals with a known DVT. The maximum rates and levels
of fXa generation occur over a 10- to 12- fold range, respectively
in both populations. This variation is larger than that observed
with thrombin (3–6 fold) [21] and demonstrates that fXa
generation is potentially a phenotypic characteristic and suggests
Figure 3. Factor Xa generation segregated by potential risk factors. Individuals within the healthy control population were separated into
categories to evaluate the response of fXa generation between groups. The groups were: Panel A) Body Mass Index (BMI); #26 kg/m
2 (n=264) and
.26 kg/m
2 (n=193); Panel B) Sex; men (n=201) and women (n=272); Panel C) Age; #45 yrs (n=223) and .45 yrs (n=250). All fXa profiles are
shown as the mean and the 95% CI.
doi:10.1371/journal.pone.0029178.g003
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thrombotic risk. The ORs for fXa generation are comparable to
those calculated from the computational analyses of thrombin
generation.
Factor Xa generation discriminated well between defined
clinical risk subgroups. Most notably, healthy women on oral
contraceptives showed .60% increase in some fXa parameters
compared to women not on oral contraceptives. In addition,
individuals with similar thrombin generation profiles displayed
differing fXa generation profiles, and there appeared to be a
linkage between the extent of the differences in the fXa generation
profiles and the timing of thrombin generation in these pairs of
individuals. Analysis of simulated fXa generation appears to be a
more sensitive discriminator than simulated thrombin generation
among individuals. In addition, these studies were performed with
a Tf-initiator concentration of 5 pM to reflect empirically
validated data [13]. Additional discrimination may be possible
when outputs are evaluated at varying Tf concentrations; further
studies are warranted to elucidate this effect.
Thrombin generation and fXa generation appear to have a
similar ability to identify individuals at risk for DVT, and can tell
us about the most thrombotic segment of the population.
However, it is not a tool for predicting which individuals in the
less thrombotic group (90% of the population) will transition to a
thrombotic state. A measure of procoagulant capacity that shows a
wider range of variation (fXa vs. thrombin generation) across an
Figure 4. Oral contraceptive use. Premenopausal women aged 15 to 49 were segregated into categories of: Panel A: control women +OC use
(n=47) and –OC use (n=90) and Panel B: women with a known DVT +OC use (n=30) and –OC use (n=40). FXa generation was evaluated for these
groups. The grey shaded area represents 1 SD.
doi:10.1371/journal.pone.0029178.g004
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prospectively identify individuals who will transition to a
procoagulant state. At the peak of prothrombinase activity, the
concentration of active fXa participating in prothrombinase
represents less than 0.004% of the zymogen fX [8].
Utilizing empirically validated mathematical modeling, investi-
gations and comparisons into protein interactions, intermediates
or complex formations can be accomplished to develop a broader
view of the dynamics associated with the coagulant response. In
this study, these simulations account for all the plasma pro- and
anti-coagulant proteins of the Tf-pathway that are both empiri-
cally validated and show correlation to clinical events and other
clinical assays. Currently, these simulations do not include the
contribution of the anticoagulant protein C pathway, the
contribution of platelets, the contact pathway or the vasculature.
In general, our theoretical approach allows us to evaluate the
impact of each individual factor to the overall fXa or thrombin
generation profile which may not be obvious using standard
multivariate methods. We have previously shown that it is the
integration of an individual’s blood composition data at any one
time into an assessment of that individual’s thrombin generation
potential that can be used to discriminate between various
hemostatic states [15,21,23] and that changes in any single input
value alone might not have any significant influence on the overall
dynamics [16,22,24,25]. Processing the input concentrations for
each subject and performing simulations gives predictive capability
beyond the original input concentrations.
Since thrombin is the key enzyme in Tf-initiated coagulation,
but requires fXa formation and function for its generation,
targeting fXa generation for analysis should increase our
knowledge regarding the results that are seen in thrombin
generation profiles. This is the first study that we are aware of
that compares fXa generation to thrombin generation in the same
population. To date, available diagnostic methods for fXa
generation include chromogenic, immunological and clot based
assays. Recently, a large focus has been on developing better
methods for detecting fXa generation with increased sensitivity
[26–28]. This focus has mainly been due to the development of
anticoagulants targeting fXa generation and the need to monitor
the efficacy. There is a greater potential for creating new targets
for evaluation of fXa dynamics through simulations than what can
be determined by empirical experiments, such as tracking fXa
formed through either the intrinsic or extrinsic complex over time
as a discriminator between subjects with high sensitivity.
The most dramatic separation of fXa generation profiles in was
between users and non-users of oral contraceptives in control
premenopausal women. The increased rate and ultimate levels of
fXa generated suggests an extremely primed procoagulant
response. The OR was similar to thrombin generation in this
group [15,21], being undefined for MaxR at a 90
th percentile and
Figure 5. Comparing factor Xa and thrombin generation. Thrombin generation profiles from the same population, previously determined
using the same methodology [15], are compared to their fXa profiles. Three pairs of overlapping individual thrombin generation profiles are shown
on the left. The dashed line indicates the mean time to the maximum level of thrombin generation within the healthy population (432 s). The
corresponding fXa generation profiles in the same individuals are shown on the right.
doi:10.1371/journal.pone.0029178.g005
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link between oral contraceptive use and thrombotic risk [29,30].
Many efforts are currently under way to decrease the risk of
thrombosis seen in women on oral contraceptives [31,32].
Previously, we have shown that women on high dose hormones,
undergoing in vitro fertilization, had increased thrombin generation
profiles [16] and that this effect on thrombin generation was in
part due to alterations in plasma factors fVIII, TFPI and AT. In
this study, we determined that the increases in fXa generation seen
in oral contraceptive users were due to elevated levels of fIX and
decreased levels of TFPI.
There is considerable interest in developing methods of analysis
that relate an individual’s thrombin generation profile derived
directly from Tf-initiation of their plasma sample to their current
or future risk of thrombosis [33]. Thrombin generation in
apparently healthy individuals has been shown to be an individual
phenotypic characteristic using either empirical approaches [34]
or plasma composition based computational modeling [15]. In
examining thrombin generation in healthy populations, there are
clearly outliers, individuals whose thrombin profiles look like
individuals with defined defects (e.g. factor deficiencies or factor
over expression). These outliers appear to be obvious candidates in
efforts to identify at risk individuals in the healthy population.
However, most healthy individuals have relatively similar
thrombin generation profiles, whether thrombin formation is
evaluated by empirical or computational methods. The signifi-
cance of small differences in these thrombin profiles is unclear, in
part because an operational definition establishing what magni-
tude of difference is required to signal a consequence to an
individual’s hemostatic balance, and thereby his/her immediate or
Figure 6. Factor Xa and thrombin generation curves for oral contraceptive users and non-users. Panel A: Factor Xa curves for oral
contraceptive users, non-users, users with fIX and TFPI adjusted to the mean value of the non-users and users with fIX, TFPI and AT adjusted to the
mean value of the non-users. Panel B: Thrombin curves for oral contraceptive users, non-users, users with fIX and TFPI adjusted to the mean value of
the non-users, users with fIX, TFPI and AT adjusted to the mean value of the non-users and users with fIX, TFPI, AT and fII adjusted to the mean value
of the non-users.
doi:10.1371/journal.pone.0029178.g006
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discriminating among these ‘‘thrombin similar’’ individuals may
be to use additional analyte(s). This study potentially identifies the
utility of fXa generation as a segregating tool for investigating
groups of such individuals.
One limitation of the computational approach is the expense of
factor analysis. We have previously reported that differences in
thrombin generation between some populations may depend only
on a subset of factors, all varying within the normal range [16,22].
This suggests the possibility that specific hemostatic states may
have a unique factor dependence thus reducing the expense in the
context of a routine screening procedure. Data from this study
shows an instance where effectively capturing differences between
populations using evaluation of simulated fXa generation depends
on a smaller subset of factor level measurements than when
simulated thrombin profiles are used as the discriminator to
evaluate the same populations. To the extent that further studies
confirm the utility of fXa generation in stratifying individuals by
clinical characteristics relevant to cardiovascular health, the
reduced requirement for factor analyses improves the feasibility
of the general approach. In addition, in this case-control study,
blood was drawn after the event. We cannot be certain that our
findings represent the situation just before the patients first deep
vein thrombosis. The case population may have inflammatory
reactions, which could affect coagulation assays. A previous
publication on CRP and fVIII do not suggest this is the case in this
group [35].
Utilizing plasma composition based modeling we can begin to
develop individual blood response profiles that can be used to
evaluate how an individual responds to varying triggers (e.g. Tf-
stimulus, antithrombotics, oral contraceptives). These approaches
can ultimately aid in the development of individualized therapies.
These studies illustrate the importance of fXa specifically and
prothrombinase as a therapeutic target.
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